Periodontal pathogens play a well documented role in the etiology of gingivitis and periodontitis.
Therapy is directed primarily towards mechanically reducing the number of pathogenic bacteria adherent to tissue. Therefore, mechanical plaque removal is the basis of most periodontal treatment regimes. For home care, different kinds of toothbrushes and dentifrices are the most frequently used oral hygiene devices (Löe 1979) . Commonly, dental plaque is disrupted supragingivally directly by mechanical action of the bristles and swept away from the dental surface. The cleaning efficacy of various toothbrush designs correlates with brushing time (Huber et al., 1985) , and is significantly enhanced by the use of toothpaste (Davis 1980; Forward 1991) . In populations without access to customary oral hygiene devices such as toothbrushes and dentifrices, up to 95% of dental surfaces exhibit visible plaque (Baelum et al., 1986) . In contrast, patients living in industrialized countries and practicing regular oral hygiene have on average only 40% to 60% of surfaces covered with plaque (Kalsbeek et al., 2000) .
It was reported, that early colonization of teeth surfaces started immediately after mechanical plaque removal. Additionally, colonization patterns were not only related to bacterial species, but also to the condition of the teeth adjacent gingiva (Saxton 1973) . Therefore, a dentifrice should provide both, plaque removal on and reduction of recolonization of dental surfaces. Most dentifrices improve the cleaning efficacy due to abrasive components and furthermore reduce recolonization by the addition of anti-microbial agents, i.e. zinc-fluoride. A new attempt to reduce bacterial colonization of tooth surfaces over and above the mechanical plaque removal is the addition of nanocrystal components to dentifrices. Hydroxyapatite nanocrystals may coat the surfaces of intra-oral bacteria and therefore reduce their ability to aggregate or co-aggregate on intra-oral surfaces. This should result in improved gingival health and lower de novo plaque formation.
The hypothesis of the projected trial is that the daily use of a newly formulated dentifrice, containing carbonate/hydroxyapatite nanocrystals , in an "over the counter model", will result in significantly lower full mouth dental plaque scores than a zinc-fluoride containing dentifrice used as a positive control.
Potential risks of the trial
There are no known risks beyond the documented risks of routine periodontal therapy and daily self performed oral hygiene with changing dentifrices. Those risks are:
• temporarily increased sensitivity of teeth (dentine hypersensitivity) to thermal, evaporative, or tactile stimuli; • nerve damage after local anesthesia (temporary or permanent);
• allergies against the ingredients of local anesthetics;
• allergies against ingredients of the dentifrices. Version 1.0 9/28 PFR Study (Plaque Formation Rate Study) 
Study Objectives and Purpose
The purpose of this study is to assess the clinical efficacy of a new dentifrice, containing carbonate/hydroxyapatite nanocrystals (BioRepair ® , Kurt Wolff Pharma, Bielefeld, Germany), in subjects suffering from severe gingivitis and/or mild to moderate chronic periodontitis and receiving non-surgical periodontal therapy. Clinical efficacy will be evaluated regarding clinical and microbiological parameters and compared to the use of a zinc-fluoride containing dentifrice (Meridol  ® , GABA, Lörrach, Germany) serving as a positive control.
Research Questions
This three-month clinical trial is conducted to answer the following research questions:
Primary Question
1. Is there a difference in de novo plaque formation as measured by the Plaque Formation Rate Index (Axelsson 1991) between subjects using the new carbonate/hydroxylapatite nanocrystal dentifrice and those using the established zinc-fluoride containing control dentifrice?
Secondary Questions
2. Are there differences between subjects using the two dentifrices with respect to their subjective perception of therapy?
3. Are there differences between the two dentifrices with respect to the following periodontal 
Study Design
The investigation is designed as a double blind, parallel group, and randomized trial over a 3-months period (primary endpoint). Secondary endpoints are not scheduled. Seventy-five subjects will be enrolled in this four-visit study; visits 1-4 are required for each subject (see Table 1 ). Test and control group subjects will be treated following identical therapy protocols, except for the dentifrice.
Participating study centers will be the Department of Periodontology at the University of Münster and 
Examiner training and calibration
The blinded examiners attend a training and calibration program aimed at reviewing the objectives of the study and the study protocol. The examiners are instructed in compilation of the case report form and in optimized patient accrual and attendance. The investigator is instructed and calibrated in the measurement technique to be employed. Calibration is performed for measurements of the dichotomous plaque index systems to ensure that 95% of differences of repeated measurements are less than two standard deviations of the mean difference between two measurements (Bland and Altman 1986 
Selection and Withdrawal of Subjects

Subject inclusion criteria
Subjects selected for the study must meet the following inclusion criteria:
• Periodontal screening index (PSI) I-III, PSI IV in at most two sextants, (except third molars); • pocket probing depths (PPDs) of ≥ 4 mm at a minimum of four teeth (except third molars);
• age ≤ 18 to ≤ 75 years;
• clinical and/or radiographic signs of severe gingivitis and/or mild to moderate chronic periodontitis; • at least 10 natural teeth in situ (except third molars);
• non-smokers (less than 3 ppm CO in exhaled air); • no professional prophylaxis during the 1 month preceding the baseline clinical evaluation;
• willingness to participate and to be available at all times required for participation;
• willingness to abstain from using antimicrobial mouthrinses for the study duration.
Subject exclusion criteria
Subjects are excluded from the study if they:
• Have known systemic diseases that may influence the periodontal conditions, in particular Down's syndrome, known AIDS/HIV or diabetes type I or II; • regularly take drugs that may affect the periodontal conditions, e.g. phenytoine, nifedipine, and/or anti-inflammatory drugs; • require antibiotic treatment for dental appointments;
• are undergoing or require extensive dental or orthodontic treatment;
• are pregnant or breastfeeding; • have rampant decay;
• any oral or extraoral piercing in or around the oral cavity with ornaments or accessory jewelry; • currently use bleaching trays or strips;
• are dental students or dental professionals;
• work for a company that produces dental products; • have participated in a clinical dental trial in the six months preceding the study.
• professional periodontal therapy during 6 months prior to baseline
Subject withdrawal criteria
Individual subjects discontinue the study if they:
• Avowedly offend against or are not willing to follow the protocol any more;
• do not keep the appointments.
Subjects are discharged from the study by filling in the subject accountability form. A replacement of withdrawn study subjects is not intended as long as a total of 30 subjects per group are not undershot. 
Subject Registration and Randomization
Subjects that fulfil all the inclusion criteria, do not meet any exclusion criteria, and have signed the informed consent will be registered into the study by the centers Münster or Würzburg (visit 1).
Subjects are assigned to a code number consisting of the one digit center code (1 or 2, see below)
and a two digit registration number (counting backwards from 99 in every participating center). At visit 2 study subjects will be randomly assigned to the test group using the carbonate/hydroxyapatite nanocrystal dentifrice or the control group using a zinc-fluoride containing dentifrice. Patient randomization is warranted by using a randomization list (block randomization with 4 subjects per block). Designation of a study subject as a smoker/non-smoker will be based on recording carbonmonoxide concentration in exhaled air (non-smoker: less than 3 ppm CO in exhaled air;
smoker: equal to or more than 3 ppm). The subjects receive the next available medication number from the center specific prepared lists (three digit medication number). This number will be fixed on the patients CRF.
Digit Center Codes:
Münster 1 Würzburg 2
Example:
Visit 1: Patients ID: 1-99 For elimination of measurement errors affecting one group of subjects more than the other, blinding is performed. Neither the clinical investigators nor the therapists, nor the study subjects themselves will be aware of the actual assignment to the test or the control group.
Treatment of subjects (Table 1 and Fig. 1)
At visit 1 ("Screening/Recruitment") all subjects are informed about the projected trial. If subjects are willing to participate, they receive periodontal screening examination (PSI) and medical history is asked. At visit 2 ("Baseline", consist of two appointments at intervals of 24 hours) within the first appointment, subjects are randomized and periodontal parameters are examined ( Table 1 ). The blinded packages of different dentifrices are dispensed to the subjects. At the end, the subjects receive routine supragingival scaling with sonic scalers and polishing with an air powder device (glycin powder). Subjects are instructed to abstain from oral hygiene for the next 24 hours. At the end, subjects fill out the two questionnaires. At the second appointment, plaque formation rate is examined and subjects are instructed to brush with their already used toothbrush for 2 minutes at least twice per day at home.
Four weeks after "Baseline" at visit 3 ("Treatment", consist of two appointments at intervals of 24 hours), periodontal parameters are examined and all subjects receive full mouth supra-and subgingival debridement in two sessions on two consecutive days. Debridement is performed with sonic scalers using micro tips under local anesthesia and polishing is performed with an air powder device. Subjects are instructed to abstain from oral hygiene for the next 24 hours. At the second appointment, plaque formation rate is examined, all subjects receive full mouth supra-and subgingival debridement, and are instructed to brush with their already used toothbrush for 2 minutes at least twice per day at home. Two months after "Treatment" at visit 4 ("Reevaluation", consist of two appointments at intervals of 24 hours) periodontal parameters are examined and all subjects receive full mouth supragingival debridement in one session. Subjects are instructed to abstain from oral hygiene for the next 24 hours. At the second appointment, plaque formation rate is examined, all subjects receive full mouth supragingival debridement. Subjects return the dentifrice packages.
Over the course of the study no medication except the dentifrice or local anesthesia is administered.
During the trial, subjects are not permitted to undergo advanced periodontal treatment (i.e. periodontal surgery) or to receive drugs influencing periodontal health. is given to the subjects. This includes:
Sequence of trial periods
• that the study is designed to evaluate the effects of two different dentifrices on periodontal health;
• that the subjects are randomly assigned to one type of dentifrice;
• the number of study visits, the approximate time needed to complete the visits (Visit 1: 15 + 15 min., Visit 2a/b: 60 + 15 min., Visit 3a/b: 120+15 min, Visit 4a/b: 45 +15 min.), the therapy, the clinical measurements, and all sampling procedures (overall 5 hours, 4 hours for routine therapy and one hour for additional study needs).
Only subjects signing the informed consent form approved by the Ethics Committee of the Medical
Council of Unterfranken, Germany, are included in the study and are given a copy of the signed consent form. The investigators fill out a screening form (see visit 1) to document that all inclusion criteria are met. All patients are informed that generally every visit b is scheduled 24 hours after the visit a, the visit 3 is scheduled 4 weeks ±7 days after visit 2, and visit 4 is scheduled 2 months ±2 weeks after visit 3.
The baseline appointments (visit 2a+b) are scheduled and all case report forms for future visits are prepared. Subjects have to be assigned consecutive numbers consisting of a total of three digits to encode the subject and the center.
Visit 2a, "Baseline"
The objective of the baseline appointment is the complete baseline examination and measurementtaking, randomization of the study subjects, plaque sampling, oral hygiene instruction, dentifrice dispensing, and supragingival debridement and completion of the questionnaires. After checking the medical health history the examiner is performing the clinical inspection of the oral cavity.
Measurements
After assessment of the gingival index, except third molars, (Löe 1967) While intraoral radiographs are being taken, the subjects are assigned randomly to test or control dentifrices using pre-defined randomization tables. Four sample teeth with at least one site with PPDs of ≥ 4 mm are determined as a sample site as shown in Fig. 2 to ensure equal distribution throughout the mouth, and remain the same over the course of the study (except third molars).
Pooled subgingival plaque samples are taken from the four sample teeth for microbiological analysis. The teeth are air dried and isolated with cotton rolls. One sterile paper point is inserted for 10 seconds in each site and all paper points are removed in one transport tube containing 500 µl
Ringer-Glycerin-Solution. The pooled samples are at once taken to the laboratory for analysis or stored in liquid nitrogen.
For supragingival samples, from the buccal and lingual sites samples are taken using Periotron 
Oral hygiene instruction
Subjects are instructed to brush with the assigned dentifrice and with their already used toothbrush for 2 minutes at least twice per day at home. No additional instructions are given, but subjects are instructed to abstain from oral hygiene for the next 24 hours.
Dentifrice package dispense
The patients receive either a dentifrice containing carbonate/hydroxyapatite nanocrystals (BioRepair ® , Kurt Wolff Pharma, Bielefeld, Germany), a zinc-fluoride containing dentifrice (Meridol ® , GABA, Lörrach, Germany) .
Supragingival debridement
All subjects receive routine full mouth supragingival debridement using sonic scalers and polishing using an air powder device (glycin powder).
Visit 2b (24 hours after Visit 2a)
After checking the medical health history the examiner is performing the clinical inspection of the oral cavity. All teeth are stained with Mira 2-Ton ® (Mirodent) and plaque formation rate index, except third molars, (Axelsson 1991 ) is examined. The Subjects receive again full mouth polishing using an air powder device (glycin powder) and are instructed to brush with their already used toothbrush for 2 minutes at least twice per day at home. 
Example:
For clockwise selection, start at the upper right quadrant from the most distal tooth going towards the mesial (CW, mandatory turn 1)
• Select the most distal tooth in this quadrant that meets the icriteria (at least one site with at least one site with PPDs of ≥ 4 mm) if one tooth is selected or none meets the criteria • continue clockwise in the upper left quadrant and now select the most mesial tooth that meets the inclusion criteria if one tooth is selected or none meets the criteria • continue clockwise in the lower left quadrant and select the most distal tooth that meets the inclusion criteria if one tooth is selected or none meets the criteria • continue clockwise in the lower right quadrant and select the most mesial tooth that meets the inclusion criteria stop if one tooth in each quadrant has been selected, if less than four teeth have been selected • continue clockwise (optional turn 2 ), and start in the upper left quadrant going from mesial towards distal • continue clockwise with optional turns 3 and 4 until a total number of 4 sample teeth have been included For counter clockwise proceed as indicated in the figure above
Visit 3a (4 weeks from baseline)
The objectives of this appointment are the clinical measurements and the collection of the plaque samples. After sampling and measurements, all subjects receive full mouth supra-and subgingival Version 1.0 17/28 debridement in two sessions on two consecutive days. After checking the medical health history the examiner is performing the clinical inspection of the oral cavity.
Measurements
After assessment of the gingival index (Löe 1967 
Microbiological samples
Plaque samples are taken as described for visit 2a.
Subgingival debridement
Debridement is performed with sonic scalers using micro tips under local anesthesia. Subgingival debridement is started in the upper right jaw and continued in the lower right jaw. In each case (visit 3a and 3b), full mouth polishing is performed using an air powder device. Subjects are instructed to refrain from brushing for the next 24 hours. No adjunctive antimicrobial therapy is administered.
Visit 3b (24 hours from Visit 3a)
After checking the medical health history the examiner is performing the clinical inspection of the oral cavity. All teeth are stained with Mira 2-Ton ® (Mirodent) and plaque formation rate index (Axelsson 1991 ) is examined. At the second day, subgingival debridement is started in the upper left jaw and continued in the lower left jaw, full mouth polishing is performed using an air powder device. The subjects are instructed to brush their teeth at least twice daily.
The reevaluation appointments (visit 4a+b) are scheduled.
Visit 4 (2 months from Treatment)
The objective of the final appointment is to perform clinical measurements, dentifrice package return, and microbiological sampling. After checking the medical health history the examiner is performing the clinical inspection of the oral cavity.
Measurements
After assessment of the gingival index (Löe 1967 Plaque samples are collected in the same manner and from the same teeth as described for visit 2a.
Dentifrice package return
The participating subjects return the dentifrice package to the test center.
Visit 4b (24 hours from Visit 4a)
After checking the medical health history the examiner is performing the clinical inspection of the oral cavity. All teeth are stained with Mira 2-Ton ® (Mirodent) and plaque formation rate index (Axelsson 1991 ) is examined. The Subjects receive again full mouth polishing using an air powder device (glycin powder).
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Specification of Psychological Assessments
At visits 2a and 4a patients are asked to complete the Oral Health Impact Profile -German Version (OHIP-G 49) and the German version of the Client Satisfaction Questionnaire (ZUF-8) as a standardized instrument used to measure health outcome.
Oral Health Impact Profile -German Version (OHIP-G 49)
The original English version of the questionnaire was developed by Slade and Spencer (1994) . The
German translation and validation of the instrument was performed by John et al. (2002) . The OHIP-G 49 contains 49 items that address specific problems of oral health, e.g., "problems with chewing of food" or "pain in the gums". Each item is assessed on a five-point scale (0: never to 4: very often). A sum score of all of the items is calculated as an indicator for current oral health. The completion of the questionnaire takes about ten minutes.
ZUF-8
The patients´ satisfaction with the treatment is evaluated by means of the Fragebogen zur Patientenzufriedenheit (ZUF-8, Schmidt et al. 1989) 
Microbiological Examination
For microbiological analysis, pooled subgingival plaque samples are taken from four different teeth with at least one site with PPDs of ≥ 4 mm from each study subject. The pooled subgingival plaque sample is collected in a transport tube containing 500 µl Ringer-Glycerin-Solution. The pooled samples are at once taken to the laboratory for analysis or stored in liquid nitrogen.
Supragingival plaque is collected from four sites per sample tooth. From the buccal and lingual sites samples are taken using Periotron© adapted to the tooth surface to collect dental plaque from the area near the gingival margin. Interproximal, supragingival plaque samples are collected by inserting a sterile paperpoint horizontally in buccal to lingual direction near the gingival margin. Samples from buccal/lingual and from interproximal sites are pooled respectively (two pooled samples from each Version 1.0 20/28 subject per visit 2a, 3a, 4a) in a seperate transport tube containing 500 µl Ringer-Glycerin-Solution.
The pooled samples are at once taken to the laboratory for analysis or stored in liquid nitrogen.
Sample teeth are randomly selected at baseline as shown in Fig. 2 to assure equal distribution throughout the mouth, and remain the same over the course of the study. The whole bacterial counts are quantified by culture at study visits 2a, 3a, and 4a.
Laboratory Processing, Microbiological Analysis
After subgingival plaque sampling, the samples are taken immediately in the laboratory for further processing or stored in liquid nitrogen until the study is finished. After finishing the trial they will be carried to Münster. For transport they are stored in carbon dioxide snow and are stored in liquid nitrogen in the laboratory in Münster again. The pooled samples are sonicated for 10 seconds (Sonotex RK 82, Bandelin Electronic AG, Berlin, Germany) and diluted in tenfold steps. 0.1 ml of the undiluted suspension and 0.1 ml aliquots of the dilutions are spread on different culture media. In parallel supragingival plaque samples are spread on CDC agar and are stored in an aerobe atmosphere at 37 degree above zero overnight.
For quantitative enumeration the undiluted and diluted suspensions are spread on non-selective blood agar (CDC agar) plates containing 5% defibrinated sheep blood supplemented with 5mg/l hemin (Merck, Darmstadt, Germany), 1 mg/l vitamin K 1 (Kleinfelder et al., 2000) , and 10 mg/l Nacetylmuramine acid (NAM). NAM is supplemented for cultivation of T. forsythensis. The plates are incubated in an atmosphere containing N 2 (85%), H 2 (10%), and CO 2 (5%) for 7 days. Total cultivable counts are assessed for each of the plaque samples. The evaluation of pooled plaque samples on CDC agar and the total cultivable counts are reported quantitatively as colony forming units (CFU/ml).
In further investigation the present of specific periodontal pathogens will be evaluated.
To assess the safety of the investigational medicinal products all adverse events occurring during the trial period will be assessed, recorded, evaluated and reported according to national regulations.
Parameters for safety are the absence of factitious, iatrogenic and accidental traumatic lesions of periodontal tissues. Any kind of serious chemical or physical gum damage that may be related to the dispensed dentifrice leads to withdrawal of the subject. A visual inspection of the integrity of the periodontal and adjacent tissues is performed at every visit. Furthermore, in the case of tissue damage all necessary therapy is initiated to avert any irreparable injury.
Definitions
Adverse event (AE)
Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Comment: An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not considered related to the investigational medicinal product.
Adverse reaction (AR)
All untoward and unintended responses to an investigational medicinal product related to any dose administered.
Comment: All adverse events judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medicinal product qualify as adverse reactions. The expression reasonable causal relationship means to convey in general that there is evidence or argument to suggest a causal relationship.
Unexpected adverse reaction (UAR)
An adverse reaction, the nature, or severity of which is not consistent with the applicable product information (e.g. investigator's brochure for an unapproved investigational product or summary of product characteristics for an authorized product).
Comments: When the outcome of the adverse reaction is not consistent with the applicable product information this adverse reaction should be considered as unexpected.
Serious adverse event or serious adverse reaction (SAE or SAR)
Any untoward medical occurrence or effect that at any dose • results in death,
• is life-threatening,
• requires hospitalization or prolongation of existing inpatients´ hospitalization,
• results in persistent or significant disability or incapacity,
• causes a congenital anomaly or a birth defect.
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• Comments:
• Life-threatening in the definition of a serious adverse event or serious adverse reaction refers to an event in which the subject was at risk of death at the time of event; it does not refer to an event which hypothetically might have caused death if it were more severe.
• Medical judgment should be exercised in deciding whether an adverse event/reaction is serious in other situations. Important adverse events/ reactions that are not immediately life-threatening or do not result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above, should also be considered serious.
Suspected unexpected serious adverse reaction (SUSAR)
A suspected serious adverse reaction that has been judged to be unexpected.
Recording and Assessment of Adverse Events (AE)
All adverse events occurring during the trial period have to be documented in the AE-form of the CRF including assessment of severity (mild: no influence on daily activities, moderate: daily activities impeded, and severe: daily activities or work not possible) and an appraisement of seriousness and causality. Additionally, it will be discriminated between expected or unexpected adverse events.
Where possible, a diagnosis rather than a list of symptoms should be given. All adverse events shall be followed up until symptoms disappear. The participating centers will report all AE's to the project manager at the coordinating center Münster. A summary of AE's will be given to the sponsor in the final report of the study.
Handling of Protocol Violations
Planned general changes in the protocol approved by the ethics committee, i.e., protocol deviations and protocol exceptions, will be submitted as formal protocol amendments or protocol exceptions to the ethics committee and must be approved prior to initiation or implementation of the change. A list of major and minor protocol violation definitions and procedures for reporting and handling them is implemented in the protocol. A protocol violation is any protocol deviation that is not approved by the ethics committee prior to the initiation.
Major violations:
a) Failure to obtain informed consent, i.e., there is no documentation of informed consent or informed consent obtained after initiation of study procedures. b) Enrollment of a subject who did not meet inclusion or exclusion criteria. c) Failure to perform required measurements and, therefore, may be affect subject safety or data integrity (i.e., baseline measurements of clinical parameters). c) Failure to follow the approved study procedures that, in the opinion of the coordinating investigator, does not affect subject safety or data integrity:
• Study procedure conducted out of sequence
• Omitting an approved portion of the protocol
• Failure to take a required sample for lab testing
• Study visit conducted outside of required timeframe d) Failure of subject to return study medication and medication diary.
e) Over-enrollment.
f) Enrollment of subjects after study expired.
Reporting and handling of protocol violations
Protocol violations may be reported either ( 
Statistical analysis
For both, primary and secondary outcome parameters, the two sampled t-test is used to test differences between the groups.
Power analyses will use data from a pilot study.
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Subject Identification List
All patient associated data are captured in a pseudonym manner. Every participating subject is distinctively assigned to a registration number consisting of one digit center code and a two digit registration code. This number is assigned at visit one. A confidential subject identification list is stored in the examiner's folder ("Prüfarztordner") existing in every participating center. In this list the registration number is connected with the patient's name.
Data Handling and Record Keeping
The study nurse provides for each subject a folder containing all case report forms (clinical and laboratory) and copies of all forms signed by the subjects during the study period. Radiographs are also to be attached to the subject's folder. The case report form is to be filled in at the time of data collection and to be signed after completion by the investigator or by the laboratory personnel responsible. The investigator and laboratory personnel are required to return the case report forms after completion of the measurements or analysis. The study nurse copies completed case report forms and originals, and copies are stored at different places. After examinations are completed, data that are entered directly in a microcomputer (i.e. all Florida Probe ® measurements) undergo daily backup on transportable media and are stored at different places. Additionally, all Florida Probe ® data are also saved as printed hard copies in the patient's folder. All data are entered continuously in a microcomputer and are checked by a second person for entry errors.
Storage of Trial Documents
The trial master file containing all study related documents will be stored, according to the national requirement for at least 15 years after completion of the final report at the coordinating center.
Additionally, copies of the forms and the investigator site file are stored for the same period at the corresponding study centers.
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This study protocol and the informed consent form are to be approved by the Ethics Committee of the
MedicalCouncil of Unterfranken, Germany
The trial will be conducted in accordance with the Declaration of Helsinki (2008 Seoul), the Principles of Good Clinical Practice and the applicable German Law.
Patient Insurance
For all subjects a patient insurance will be contracted.
Study Information and Informed Consent
Prior to registration into the trial, every subject willing to participate in the trial is informed by the clinical investigator at the participating center about the character, the impact, as well as the risks and benefits of the trial. Additionally, subjects get informed that they are entitled to quit participation at all time without drawbacks concerning further periodontal therapy at the respective Department of
Periodontology. In accordance with the MPG, patients are informed that disease associated data will be saved pseudonymously and will be used for scientific publications. This is documented by an intelligible study information and informed consent document (one document) signed by the patient.
After signing the patient get a copy of this document (for study information and informed consent see the appendix).
Financing
The trial is exclusively funded by Dr. Kurt Wolff GmbH & Co. KG, Bielefeld, Germany.
Compliance with the Trial Protocol
All procedures concerning the present trial have to be executed conform to the definitions and instructions as given in this protocol. Every protocol deviation by the investigator concerning the scheduled measurements and treatments or scheduled the time flow has to be documented and justified (e.g. in case of emergency).
The advances in the ongoing trial, especially the scheduled recruitment rates of the participating centers, are documented in every participating center and transmitted to the coordinating investigator by a monthly report.
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